title: Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy.
abstract: BACKGROUND
  Sirolimus (RAPA) and corticosteroids (CS) both inhibit wound healing. To evaluate the possibility that RAPA and CS have additive effects on wound healing, we evaluated the effects of corticosteroid avoidance (CSAV) on wound healing complications in patients treated with RAPA.
  
  
  METHODS
  One hundred nine patients treated with a CSAV regimen (no pretransplantation or posttransplantation CS) were compared with a historical control group (n = 72) that received cyclosporine (CsA), mycophenolate mofetil (MMF), and CS. The CSAV group received low-dose CsA, MMF, RAPA, and thymoglobulin induction. Complications were classified as follows: wound healing complications (WHC) or infectious wound complications (IWC). WHC included lymphocele, hernia, dehiscence, diastasis, and skin edge separation. IWC included wound abscess and empiric antibiotic therapy for wound erythema.
  
  
  RESULTS
  The CSAV group was largely CS-free: 11% of patients received CS for rejection, 12% of patients received CS for recurrent disease, and 85% of patients are currently off CS. The CSAV group had a significantly lower incidence of WHC (13.7% vs 28%; P = .03) and lymphoceles (5.5% vs 16%; P = .02) than the control group. There was no difference in the incidence of IWC between the 2 groups. Patients who received CSAV were 18% less likely (P = .57) to develop any type of complication, 41% less likely (P = .20) to develop a WHC, and 71% less likely (P = .018) to develop a lymphocele.
  
  
  CONCLUSIONS
  CSAV in a RAPA-based regimen results in a marked reduction in WHC and lymphoceles. Therefore, CSAV provides a promising approach for addressing WHC associated with RAPA therapy.
authors.affiliation: Department of Surgery, Division of Transplantation, University of Cincinnati, Cincinnati, Ohio 45267-0558, USA.
authors.forename: C C
authors.initials: CC
authors.lastname: Rogers
authors.forename: M
authors.initials: M
authors.lastname: Hanaway
authors.forename: R R
authors.initials: RR
authors.lastname: Alloway
authors.forename: J W
authors.initials: JW
authors.lastname: Alexander
authors.forename: R E
authors.initials: RE
authors.lastname: Boardman
authors.forename: J
authors.initials: J
authors.lastname: Trofe
authors.forename: M
authors.initials: M
authors.lastname: Gupta
authors.forename: T
authors.initials: T
authors.lastname: Merchen
authors.forename: J F
authors.initials: JF
authors.lastname: Buell
authors.forename: M
authors.initials: M
authors.lastname: Cardi
authors.forename: P
authors.initials: P
authors.lastname: Roy-Chaudhury
authors.forename: P
authors.initials: P
authors.lastname: Succop
authors.forename: E S
authors.initials: ES
authors.lastname: Woodle
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects*; D016572:Cyclosporine / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000601:surgery; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008210:Lymphocele / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D020123:Sirolimus